Human Pluripotent Stem Cell-Based Models for Predictive Developmental Neural Toxicity

Patent metadata

Field	Value
Publication number	US-2022017873-A1
Application number	US-202117373523-A
Country	US
Kind code	A1
Filing date	Jul 12, 2021
Priority date	Dec 31, 2014
Publication date	Jan 20, 2022
Grant date	—

Abstract

The present invention relates to three-dimensional (3D) tissue constructs and methods of using such 3D tissue constructs to screen for neurotoxic agents. In particular, provided herein are methods of producing and using complex, highly uniform human tissue models comprising physiologically relevant human cells, where the tissue models have the degree of sample uniformity and reproducibility required for use in quantitative high-throughput screening applications.

First claim

1 - 26 . (canceled)

27 . A method of producing a vascularized neural tissue construct, comprising
(a) seeding a three-dimensional porous material with human neural progenitor cells; (b) culturing the seeded material for a length of time sufficient to detect differentiation of at least a portion of the neural progenitor cells; (c) dispersing, on or within the cultured seeded material, human endothelial cells; and (d) culturing the seeded material comprising the dispersed human endothelial cells under culture conditions that promote cell differentiation, whereby a vascularized neural tissue construct comprising human neurons and glial cells is produced, wherein the porous material is proteolytically degradable.

28 . The method of claim 27 comprising, in step (c), further dispersing, on or within the cultured seeded material, one or more of human mesenchymal cells, primitive macrophages, and pericytes.

29 . The method of claim 27 , wherein the three-dimensional porous material is a hydrogel.

30 . The method of claim 29 , wherein the hydrogel comprises polymerized poly(ethylene glycol) (PEG) or polymerized polysaccharide.

31 . The method of claim 27 , wherein the dispersed human endothelial cells are derived from a human pluripotent stem cell.

32 . The method of claim 31 , wherein the human pluripotent stem cell is an embryonic stem cell or an induced pluripotent stem cell.

33 . The method of claim 27 , wherein the seeded material comprising the dispersed human endothelial cells further comprises human pluripotent stem cell-derived primitive macrophages and wherein the three-dimensional vascularized neural tissue construct comprises mature microglia.

34 . The method of claim 27 , wherein seeding the porous material comprises contacting to the porous material at least one human neural progenitor cell.

35 . The method of claim 27 further comprising dispersing within or on the porous material a bioactive agent that modulates a morphological feature, function, or differentiation status of a cell seeded or dispersed therein.

36 . The method of claim 35 , wherein the bioactive agent is selected from the group consisting of a growth factor, a cytokine, and a bioactive peptide, or a combination thereof.

37 . The method of claim 27 , wherein the vascularized neural tissue construct exhibits one or more properties selected from the group consisting of: (i) an interconnected vasculature; (ii) differentiated cells within the neural tissue construct mutually contact each other in three dimensions; (iii) more than one layer of cells; and (iv) a function or property characteristic of human neural tissue in vivo or in situ.

38 . The method of claim 27 , wherein the neurons and glial cells are selected from the group consisting of GABAergic neurons, glutamatergic neurons, astrocytes, and oligodendrocytes.

39 . A three-dimensional (3D) vascularized neural tissue construct obtained according to the method of claim 27 .

40 . The neural tissue construct of claim 39 , comprising mature microglia.

41 . The neural tissue construct of claim 39 , comprising stratified layers of neurons and glia.

Assignees

• Wisconsin Alumni Res Found

Inventors

• Thomson James A
• Murphy William L
• Page Charles D
• Schwartz Michael P
• Hou Zhonggang

Classifications

• C12N2502/1358

  Bone marrow mesenchymal stem cells (BM-MSC) · CPC title

• C12N2502/28

  Vascular endothelial cells · CPC title

• C12N2503/02

  Drug screening · CPC title

• C12N5/0622

  Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells · CPC title

• C12Q1/6883

  for diseases caused by alterations of genetic material · CPC title